What is Hualan Biological Engineering Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, Hualan Biological Engineering has a Sloan Ratio of 4.24%, indicating the company is in the safe zone and there is no funny business with accruals.
Hualan Biological Engineering Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hualan Biological Engineering's Sloan Ratio %
For the Biotechnology subindustry, Hualan Biological Engineering's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hualan Biological Engineering's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Hualan Biological Engineering's Sloan Ratio % falls into.
Hualan Biological Engineering Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Hualan Biological Engineering's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 174.976 (Jun. 2023 ) + 540.634 (Sep. 2023 ) + 414.293 (Dec. 2023 ) + 261.774 (Mar. 2024 ) = ¥1,392 Mil.
Hualan Biological Engineering's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 398.156 (Jun. 2023 ) + -74.766 (Sep. 2023 ) + 653.221 (Dec. 2023 ) + 50.186 (Mar. 2024 ) = ¥1,027 Mil.
Hualan Biological Engineering's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 531.522 (Jun. 2023 ) + -342.288 (Sep. 2023 ) + -450.384 (Dec. 2023 ) + -64.143 (Mar. 2024 ) = ¥-325 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hualan Biological Engineering (SZSE:002007) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Hualan Biological Engineering has a Sloan Ratio of 4.24%, indicating the company is in the safe zone and there is no funny business with accruals.
Hualan Biological Engineering Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Hualan Biological Engineering's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Hualan Biological Engineering (SZSE:002007) Business Description
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:002007 has been successfully added to your 